Product image of Lacosamide Neuraxpharm (Lacosamide) supplied by GNH India

Lacosamide Neuraxpharm

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamide Neuraxpharm (Lacosamide)

Lacosamide, the active ingredient in Lacosamide Neuraxpharm, is a sodium channel blocker presented as an oral dosage form for oral use. It is indicated for the treatment of partial‑onset seizures and other forms of epilepsy in adult patients.

GNH India supplies Lacosamide Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality manufacturing according to EU standards and provides regulatory support for global distribution.

Manufacturer / TM Owner

Neuraxpharm Arzneimittel Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide is used in the management of seizure disorders that involve abnormal neuronal firing.

  • Partial‑onset seizures: reduces seizure frequency and severity in patients with focal epilepsy.
  • Focal epilepsy: provides adjunctive control of seizures when monotherapy is insufficient.
  • Refractory epilepsy: serves as an additional option for patients whose seizures are not adequately controlled by other antiepileptic drugs.

How It Works

  • Lacosamide selectively enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing the inactive state of these channels, it diminishes repetitive neuronal firing and lowers hyperexcitability that underlies seizure generation. The drug does not significantly affect fast inactivation, allowing normal neuronal activity to continue while suppressing pathological discharges.

Side Effects

Lacosamide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Dizziness
  • Headache
  • Nausea
  • Fatigue

Serious or Rare Side Effects

  • Stevens‑Johnson syndrome or toxic epidermal necrolysis
  • Cardiac conduction abnormalities (e.g., PR‑interval prolongation)
  • Suicidal thoughts or behavior

Precautions & Warnings

When prescribing Lacosamide, clinicians should consider several safety aspects to minimize risk.

  • Renal impairment: dose adjustment may be required in patients with reduced kidney function.
  • Hepatic impairment: monitor liver enzymes and adjust dose if significant dysfunction is present.
  • Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation or arrhythmias.
  • Concomitant antiepileptic drugs: assess for additive CNS depression or pharmacokinetic interactions.
  • Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
  • Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Lacosamide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers (e.g., carbamazepine, phenytoin, phenobarbital): may markedly reduce lacosamide plasma levels.
  • Co‑administration with other sodium‑channel blockers (e.g., carbamazepine): increases risk of cardiac conduction effects.
  • QT‑prolonging agents (e.g., quinidine): may exacerbate cardiac rhythm disturbances.

Moderate Interactions (Monitor Closely)

  • Alcohol: can enhance central nervous system depression and dizziness.
  • Other antiepileptic drugs (e.g., valproate, levetiracetam): may require therapeutic monitoring for seizure control.
  • CYP2C19 inhibitors (e.g., fluconazole): can increase lacosamide concentrations modestly.

Frequently Asked Questions

Lacosamide Neuraxpharm is a prescription antiepileptic medication indicated for the treatment of partial‑onset seizures and other forms of focal epilepsy in adult patients. It is used as adjunct therapy to help achieve better seizure control when monotherapy is insufficient.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilizing them in an inactive state. This reduces repetitive neuronal firing and lowers hyperexcitability, thereby decreasing the likelihood of seizure generation without markedly affecting normal neuronal activity.

The appropriate dosage of Lacosamide Neuraxpharm is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and renal or hepatic function. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for lacosamide in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation rather than fast inactivation, offering a different safety profile and potentially fewer drug‑interaction concerns. It is often chosen as an adjunct when other agents have not achieved adequate seizure control.

The product should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use it after the expiration date.

Lacosamide Neuraxpharm is taken orally, usually as a tablet, and should be swallowed whole with water. It may be taken with or without food, and the dosing schedule should follow the prescriber’s directions to maintain consistent blood levels.

The most serious adverse reactions include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, cardiac conduction abnormalities like PR‑interval prolongation, and emergence of suicidal thoughts or behavior. Patients should seek immediate medical attention if any of these occur.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and it should be avoided in individuals with significant cardiac conduction disorders, such as marked PR‑interval prolongation, unless closely monitored by a cardiologist.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT